NCT06087055 is a Phase 1 clinical trial of GST-HG171/Ritonavir in Healthy Participant, sponsored by Fujian Akeylink Biotechnology Co., Ltd..

Who is sponsoring NCT06087055?

NCT06087055 is sponsored by Fujian Akeylink Biotechnology Co., Ltd..

What drugs are being tested in NCT06087055?

Interventions in NCT06087055: GST-HG171/Ritonavir, Itraconazole, GST-HG171/Ritonavir.

What condition does NCT06087055 study?

NCT06087055 studies Healthy Participant.

Is NCT06087055 still recruiting?

NCT06087055 is currently completed. Last updated 17 October 2023.

Last reviewed 2023-10-17 · How we verify

NCT06087055

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants

Completed Phase 1 Last updated 17 October 2023

What this trial tests

Phase 1 trial testing GST-HG171/Ritonavir in Healthy Participant in 12 participants. Completed in 7 August 2023.

Timeline

12 May 2023

Primary endpoint
5 June 2023

7 August 2023

Quick facts

Lead sponsor	Fujian Akeylink Biotechnology Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	12
Start date	12 May 2023
Primary completion	5 June 2023
Estimated completion	7 August 2023
Sites	1 location across China

Drugs / interventions tested

GST-HG171/Ritonavir — full drug profile →
Itraconazole — full drug profile →
GST-HG171/Ritonavir — full drug profile →

Conditions studied

Healthy Participant — all drugs for Healthy Participant →

Sponsor

Fujian Akeylink Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 18 to 50, any sex, with Healthy Participant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of GST-HG171/ritonavir in healthy participants.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents.
Zagórska A, Czopek A, Fryc M, Jończyk J. · · 2024 · cited 19× · PMID 39062511 · DOI 10.3390/biom14070797
Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects.
Li X, Li B, Wang M, Wang J, et al · · 2026 · PMID 42112804 · DOI 10.1128/aac.00285-26

Verify or expand the search:

Other trials of GST-HG171/Ritonavir

Trials testing the same drug.

NCT05656443 — Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19 · Phase 2, PHASE3 · completed

Other recruiting trials for Healthy Participant

Currently open trials in the same condition.

NCT07455240 — A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults · Phase 1 · active not recruiting
NCT07153159 — A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding · Phase 1 · recruiting

Other Fujian Akeylink Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT07090759 — To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) · Phase 3 · recruiting
NCT06263959 — A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 · Phase 2 · recruiting
NCT06084507 — Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants · Phase 1 · unknown
NCT06106126 — Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function · NA · unknown
NCT05637541 — Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06087055 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Akeylink Biotechnology Co., Ltd.
Last refreshed: 17 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06087055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing